Preclinical safety evaluation of IQG-607 in rats: Acute and repeated dose toxicity studies
- 1 June 2017
- journal article
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 86, 11-17
Abstract
No abstract availableKeywords
Funding Information
- Banco Nacional de Desenvolvimento Econômico e Social (BNDES/FUNTEC)
- National Institute of Science and Technology
- FINEP
- FAPERGS-CNPq-PRONEX-2009
This publication has 9 references indexed in Scilit:
- IQG-607 abrogates the synthesis of mycolic acids and displays intracellular activity against Mycobacterium tuberculosis in infected macrophagesInternational Journal of Antimicrobial Agents, 2014
- Activity of IQG-607, a new orally active compound, in a murine model of Mycobacterium tuberculosis infectionInternational Journal of Antimicrobial Agents, 2012
- One-generation reproductive toxicity study of 2-methylbutane in Sprague–Dawley ratsRegulatory Toxicology and Pharmacology, 2011
- The challenge of new drug discovery for tuberculosisNature, 2011
- An inorganic complex that inhibits Mycobacterium tuberculosis enoyl reductase as a prototype of a new class of chemotherapeutic agents to treat tuberculosisJournal of the Brazilian Chemical Society, 2010
- The Mode of Inhibition of Mycobacterium tuberculosis Wild-Type and Isoniazid-Resistant 2-Trans-Enoyl-ACP(CoA) Reductase Enzymes by An Inorganic ComplexAnti-Infective Agents, 2008
- Slow-Onset Inhibition of 2-trans-Enoyl-ACP (CoA) Reductase from Mycobacterium tuberculosis by an Inorganic ComplexCurrent Pharmaceutical Design, 2006
- An inorganic iron complex that inhibits wild-type and an isoniazid-resistant mutant 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosisChemical Communications, 2004
- Preclinical safety evaluation of moxifloxacin, a novel fluoroquinoloneJournal of Antimicrobial Chemotherapy, 1999